Skip to main content

Table 2 Basic patient and tumor characteristics according to treatment arm and in the entire study population

From: Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study

 

Treatment arm

E–T–CMF

ET–CMF

Total

Patients

 N

324

339

663

Age in years

 Mean (SD)

54.2 (11.1)

53.9 (11.3)

54.0 (11.2)

 Min–Max

29–79

22–76

22–79

 

N (%)

N (%)

N (%)

Adjuvant hormonal therapy

 Yes

234 (74.3)

252 (77.3)

486 (75.8)

 No

81 (25.7)

74 (22.7)

155 (24.2)

 Not reported

9 (2.8)

13 (3.8)

22 (3.3)

Adjuvant radiotherapy

 Yes

220 (71.0)

260 (80.0)

480 (75.6)

 No

90 (29.0)

65 (20.0)

155 (24.4)

 Not reported

14 (4.3)

14 (4.1)

28 (4.2)

Age

 <50

117 (36.1)

123 (36.2)

240 (36.2)

 ≥50

207 (63.9)

216 (63.8)

423 (63.8)

EGFR protein expression

 Positive

50 (15.9)

46 (14.4)

96 (15.2)

 Negative (<1%)

264 (84.1)

273 (85.6)

537 (84.8)

 Not reported

10 (3.1)

20 (5.9)

30 (4.5)

ER/PgR status

 Negative

84 (26.0)

85 (25.1)

169 (25.5)

 Positive

239 (74.0)

254 (74.9)

493 (74.5)

 Not reported

1 (0.3)

 

1 (0.2)

Histological grade

 I–II

154 (47.5)

172 (50.8)

326 (49.2)

 III-undifferentiated

170 (52.5)

167 (49.2)

337 (50.8)

HER2 protein expression

 Overexpression

92 (29.3)

103 (31.5)

195 (30.4)

 No overexpression

222 (70.7)

224 (68.5)

446 (69.6)

 Not reported

10 (3.1)

12 (3.5)

22 (3.3)

HER2 status (IHC/FISH)

 Negative

241 (77.5)

248 (77.3)

489 (77.4)

 Positive

70 (22.5)

73 (22.7)

143 (22.6)

 Not reported

13 (4.0)

18 (5.3)

31 (4.7)

Histological type

 Invasive ductal

261 (80.6)

268 (79.1)

529 (79.8)

 Invasive lobular

27 (8.3)

37 (10.9)

64 (9.6)

 Mixed

22 (6.8)

19 (5.6)

41 (6.2)

Other

14 (4.3)

15 (4.4)

29 (4.4)

Interval from operation

 <2 weeks

27 (8.3)

22 (6.5)

49 (7.4)

 2–4 weeks

144 (44.6)

147 (43.5)

291 (44.0)

 >4 weeks

152 (47.1)

169 (50.0)

321 (48.6)

 Not reported

1 (0.3)

1 (0.3)

2 (0.3)

Menopausal status

 Pre

137 (42.3)

145 (42.8)

282 (42.6)

 Post

187 (57.7)

194 (57.2)

381 (57.4)

Number of positive nodes

 1–3

143 (44.1)

159 (46.9)

302 (45.6)

 ≥4

181 (55.9)

180 (53.1)

361 (54.4)

Tumor size

 ≤2 cm

90 (27.8)

107 (31.6)

197 (29.8)

 >2 cm

234 (72.2)

232 (68.4)

466 (70.2)

Subtype classification

 Luminal A

93 (30.5)

97 (30.3)

190 (30.4)

 Luminal B

105 (34.4)

112 (35.0)

217 (34.7)

 Luminal-HER2

35 (11.5)

44 (13.7)

79 (12.6)

 HER2-enriched

35 (11.5)

29 (9.1)

64 (10.3)

 Triple-negative

37 (12.1)

38 (11.9)

75 (12.0)

 Not reported

19 (5.9)

19 (5.6)

38 (5.7)

Type of surgery

 Modified radical mastectomy

219 (67.6)

227 (67.0)

446 (67.3)

 Breast-conserving

105 (32.4)

112 (33.0)

217 (32.7)

  1. Patient characteristics were well balanced between the two arms.